174 related articles for article (PubMed ID: 31486117)
1. Biosimilar and interchangeable: Inseparable scientific concepts?
de Mora F; Balsa A; Cornide-Santos M; Carrascosa JM; Marsal S; P Gisbert J; Abad MA; F Duarte R; Wiechmann M; Martínez R
Br J Clin Pharmacol; 2019 Nov; 85(11):2460-2463. PubMed ID: 31486117
[No Abstract] [Full Text] [Related]
2. Interchangeability Of Biological Drug Products-FDA Draft Guidance.
Endrenyi L; Markus R
J Biopharm Stat; 2019; 29(6):1003-1010. PubMed ID: 31023141
[TBL] [Abstract][Full Text] [Related]
3. Sowing confusion in the field: the interchangeable use of biosimilar terminology.
McKinley L; Kelton JM; Popovian R
Curr Med Res Opin; 2019 Apr; 35(4):619-621. PubMed ID: 30556742
[TBL] [Abstract][Full Text] [Related]
4. Scientific factors and current issues in biosimilar studies.
Chow SC; Endrenyi L; Lachenbruch PA; Mentré F
J Biopharm Stat; 2014; 24(6):1138-53. PubMed ID: 25098559
[TBL] [Abstract][Full Text] [Related]
5. Clinical development and trial design of biosimilar products: a Japanese perspective.
Nagasaki M; Ando Y
J Biopharm Stat; 2014; 24(6):1165-72. PubMed ID: 25033370
[TBL] [Abstract][Full Text] [Related]
6. The nocebo effect challenges the non-medical infliximab switch in practice.
Boone NW; Liu L; Romberg-Camps MJ; Duijsens L; Houwen C; van der Kuy PHM; Janknegt R; Peeters R; Landewé RBM; Winkens B; van Bodegraven AA
Eur J Clin Pharmacol; 2018 May; 74(5):655-661. PubMed ID: 29368188
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of the biosimilar CT-P13.
Yoo DH
J Comp Eff Res; 2017 Nov; 6(8):693-712. PubMed ID: 29172717
[TBL] [Abstract][Full Text] [Related]
8. [Biological and biosimilar drugs: Clarifying concepts].
Rodriguez Cumplido D; Asensio Ostos C
Aten Primaria; 2018; 50(6):323-324. PubMed ID: 29605234
[No Abstract] [Full Text] [Related]
9. [Biosimilars].
Krämer I
Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
[TBL] [Abstract][Full Text] [Related]
10. Infliximab or biosimilars in sarcoidosis; to switch or not to switch?
Veltkamp M; Drent M; Baughman RP
Sarcoidosis Vasc Diffuse Lung Dis; 2016 Jan; 32(4):280-3. PubMed ID: 26847093
[No Abstract] [Full Text] [Related]
11. Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review.
Gisbert JP; Chaparro M
Gastroenterol Hepatol; 2018; 41(6):389-405. PubMed ID: 29753532
[TBL] [Abstract][Full Text] [Related]
12. Demystifying biosimilars: development, regulation and clinical use.
Rugo HS; Rifkin RM; Declerck P; Bair AH; Morgan G
Future Oncol; 2019 Mar; 15(7):777-790. PubMed ID: 30500264
[TBL] [Abstract][Full Text] [Related]
13. [Biosimilars in the European Union: current situation and challenges].
Wolff-Holz E; Weise M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2020 Nov; 63(11):1365-1372. PubMed ID: 33034693
[TBL] [Abstract][Full Text] [Related]
14. Biosimilars for psoriasis: clinical studies to determine similarity.
Blauvelt A; Puig L; Chimenti S; Vender R; Rajagopalan M; Romiti R; Skov L; Zachariae C; Young H; Prens E; Cohen A; van der Walt J; Wu JJ
Br J Dermatol; 2017 Jul; 177(1):23-33. PubMed ID: 27639072
[TBL] [Abstract][Full Text] [Related]
15. FDA Expectations for Demonstrating Interchangeability.
Chance K
Ther Innov Regul Sci; 2018 May; 52(3):369-373. PubMed ID: 29714562
[TBL] [Abstract][Full Text] [Related]
16. Statistical methods for assessing interchangeability of biosimilars.
Chow SC; Yang LY; Starr A; Chiu ST
Stat Med; 2013 Feb; 32(3):442-8. PubMed ID: 22899372
[TBL] [Abstract][Full Text] [Related]
17. On the interchangeability of biologic drug products.
Endrenyi L; Chang C; Chow SC; Tothfalusi L
Stat Med; 2013 Feb; 32(3):434-41. PubMed ID: 22911936
[TBL] [Abstract][Full Text] [Related]
18. Are we ready to close the discussion on the interchangeability of biosimilars?
Ebbers HC; Schellekens H
Drug Discov Today; 2019 Oct; 24(10):1963-1967. PubMed ID: 31254488
[TBL] [Abstract][Full Text] [Related]
19. Interchangeability of biosimilar and biological reference product: updated regulatory positions and pre- and post-marketing evidence.
Trifirò G; Marcianò I; Ingrasciotta Y
Expert Opin Biol Ther; 2018 Mar; 18(3):309-315. PubMed ID: 29186988
[TBL] [Abstract][Full Text] [Related]
20. Clinical experience with infliximab biosimilar in psoriasis.
Ricceri F; Pescitelli L; Lazzeri L; Prignano F
Br J Dermatol; 2017 Dec; 177(6):e347-e348. PubMed ID: 28646577
[No Abstract] [Full Text] [Related]
[Next] [New Search]
